Loading...

HRP Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Horseradish Peroxidase, SAv-HRP
Ave. Rating
Submit a Review
Product Citations
publications
Cat # Size Price Save
405210 1 mL ¥28,380
Description

Streptavidin binds to biotin with high affinity. Streptavidin-HRP is useful for detecting biotinylated antibodies, e.g., in ELISA, ELISPOT, IHC or Western blotting. For ELISA applications, HRP will act on soluble substrates, such as ABTS or TMB, to yield a colorimetric reaction. For ELISPOT or Western blotting applications, HRP will act on precipitating substrates, such as 4CN, to yield a colorimetric reaction.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Buffered solution containing bovine protein and preservatives (methylisothiazolone, bromonitrodioxane, and other active isothiazolones).
Preparation
Streptavidin is conjugated with horseradish peroxidase under optimal conditions.
Storage & Handling
The streptavidin-HRP solution should be stored undiluted between 2°C and 8°C. Avoid exposure to sodium azide.

To obtain lot-specific expiration date, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)

This product has a shelf-life of 12 months or less. Please use our Expiration Lookup Tool to verify the expiration date of your lot of product
Application

ELISA - Quality tested
ELISPOT, WB, IHC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this Streptavidin-HRP is quality control tested by ELISA assay. For ELISA or Western blot analysis, the reagent should be titrated between 1:1000 - 1:3000 to determine optimal conditions. For ELISPOT analysis, the reagent should be titrated between 1:500 - 1:1500 to determine optimal conditions. Avoid using biotin-containing solutions as diluents and solutions containing sodium azide. Sodium azide is an inhibitor of horseradish peroxidase. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Streptavidin-HRP is useful as a second step reagent for indirect enzymatic labelling, in conjunction with biotinylated primary antibodies. Sav-HRP is recommended for ELISA, ELISPOT and Western blotting, when used with the relevant substrate system.

Application References

(PubMed link indicates BioLegend citation)
  1. Li KJ, et al. 2006. J. Leukoc. Biol. doi:10.1189/jlb.1105668.PubMed
  2. Weldon S, et al. 2009. J. Immunol. 183:8148. PubMed
  3. Basnayake K, et al. 2010. J Am Soc Naphrol. 21:1165. PubMed
  4. Marder W, et al. 2011. Ann Rheum Dis. PubMed
  5. Cheng J, et al. 2012. Mol Biol Cell. 23:2891. PubMed
  6. Vishwakarma V, et al. 2012. Infect Immun. 80:3236. PubMed
  7. Sun X, et al. 2013. J. Immunol. 190:2536. PubMed
  8. Van Phan T, et al. 2013. Biochem Pharmacol. 85:1145. PubMed
  9. Ranganathan P, et al. 2013. J Rhematol. 40:129. PubMed
  10. Din Su, et al. 2013. Occup Med. PubMed
  11. Bulut GB, et al. 2013. Blood. 122:3964. PubMed
  12. Chia YL, et al. 2013. Antiviral Res. 3542:354. PubMed
  13. Ahn JM, et al. 2014. Mol Cell Proteomics. 13:30. PubMed
  14. Din SU, et al. 2014. Occup Med. 64:39. PubMed
  15. Balmer ML, et al. 2014. Sci Transl Med. 21:237. PubMed
  16. Klehmet J, et al. 2014. J Neurol Neurosurg Psychiatry. PubMed
  17. Wu CC, et al. 2014. Cancer Epidemiol. Biomarkers Prev. 23:1569. PubMed
  18. Peng JG, et al. 2014. J Virol. 88:8386. PubMed
  19. Chlon TM, et al. 2014. J Virol. 88:11315. PubMed
  20. Sadovskaya I, et al. 2014. Carbohydr Poly. 111:139. PubMed
  21. Liu T, et al. 2015. Infect Immun. 83:2011. PubMed
  22. Himmelein S, et al. 2015. J Virol. 89:5747. PubMed
  23. Dinter J, et al. 2015. J Mol Endocrinol. 54:205. PubMed
  24. Yang L, et al. 2015. J Immunol. 194:5635. PubMed
Product Citations
  1. Wang YH, et al. 2018. Oncol Lett. 16:6903. PubMed
  2. Zhang C, et al. 2015. J Surgical Res. 197: 301-306. PubMed
  3. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  4. Csobán-Szabó Z, et al. 2021. Int J Mol Sci. 22:. PubMed
  5. Lopez-Gordo E, et al. 2022. Front Med (Lausanne). 8:732095. PubMed
  6. Tabynov K, et al. 2022. NPJ Vaccines. 7:24. PubMed
  7. Clemente V, et al. 2022. Cancer Res Commun. 2:784. PubMed
  8. Laver JR, et al. 2021. Sci Transl Med. 13: . PubMed
  9. Wang Q, et al. 2022. EMBO J. 41:e110636. PubMed
  10. Johnson BS, et al. 2022. Mol Cell Proteomics. 21:100256. PubMed
  11. Ye D, et al. 2022. J Pineal Res. 73:e12828. PubMed
  12. Gao SS, et al. 2022. iScience. 25:105481. PubMed
  13. He Q, et al. 2023. Life Sci Alliance. 6: . PubMed
  14. Cho YK, et al. 2022. Sci Adv. 8:eabq4022. PubMed
  15. Qin J, et al. 2023. Front Immunol. 14:1126392. PubMed
  16. Watanabe T, et al. 2020. Cytotherapy. . PubMed
  17. Gendron D, et al. 2017. Pulm Pharmacol Ther. 10.1016/j.pupt.2017.03.010. PubMed
  18. Kongsuphol P, et al. 2022. Commun Med (Lond). 1:46. PubMed
  19. Kikuchi N, et al. 2019. Biol Pharm Bull. 42:57. PubMed
  20. Cheng J, et al. 2012. Mol Biol Cell. 23:2891. PubMed
  21. Tu S, et al. 2015. Nature. 534:387-390. PubMed
  22. Brugiroux S, et al. 2016. Nat Microbiol. 2:16215. PubMed
  23. Gamache J, et al. 2019. Nat Commun. 10:2479. PubMed
  24. Hooper K, Kong W, Ganea D, et al. 2017. PLoS One. 12(6):e0179184. PubMed
  25. Li Q, et al. 2020. Cell Stem Cell. 675:26. PubMed
  26. Himmelein S, et al. 2015. J Virol. 89:5747. PubMed
  27. Ahn J, et al. 2014. Mol Cell Proteomics. 13:30. PubMed
  28. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  29. Fan X, et al. 2021. Int J Mol Sci. 22:. PubMed
  30. Cárdenas–Torres FI, et al. 2019. Medicina (Kaunas). 55:3. PubMed
  31. Duan S, et al. 2019. J Clin Invest. 129:1387. PubMed
  32. Wu J 2014. J Virol. 88:8386. PubMed
  33. Sielemann J, et al. 2021. Nat Commun. 12:6549. PubMed
  34. Marder W, et al. 2011. Ann Rheum Dis. 70:1550. PubMed
  35. Li K, et al. 2006. J Leukoc Biol . 80:350. PubMed
  36. Hwang D, et al. 2016. PLoS One. 11: 0152522. PubMed
  37. Asarnow D, et al. 2021. Cell. 184:3192. PubMed
  38. Nakanishi M, et al. 2019. Cell. 177:910. PubMed
  39. Vishwakarma V, et al. 2012. Infect Immun . 80:3236. PubMed
  40. Weldon S, et al. 2009. J Immunol. 183:8148. PubMed
  41. Czakai K, et al. 2016. Sci Rep. 6:27990. PubMed
  42. Duan S, et al. 2021. J Immunol. 206:2290. PubMed
  43. Phillips AT, et al. 2021. Invest Ophthalmol Vis Sci. 62:15. PubMed
  44. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
  45. Counoupas C, et al. 2020. NPJ Vaccines. 0.28125. PubMed
  46. Morita M, et al. 2021. Heliyon. 7:e06228. PubMed
  47. MÜller A, et al. 2016. PLoS One. 11:e0168260. PubMed
  48. Crowley SJ, et al. 2020. Open Biol. 10:190235. PubMed
  49. Tidley S 2014. Occup Med. 64:39. PubMed
  50. Ye F, et al. 2016. J Virol. 90: 9654 - 9663. PubMed
  51. Tuladhar R, et al. 2019. J Biol Chem. 294:6273. PubMed
  52. Gröschel C, et al. 2017. Sci Rep.. 10.1038/s41598-017-16147-1. PubMed
  53. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  54. Morgan R, et al. 2016. PLoS One. 11: 0162008. PubMed
  55. Chlon T, et al. 2014. J Virol. 88:11315. PubMed
  56. Shukla SP, et al. 2021. Int J Mol Sci. 22:. PubMed
  57. Simic MS, et al. 2019. Sci Adv. 5:eaaw0025. PubMed
  58. Herp S, et al. 2019. Cell Host Microbe. 25:681. PubMed
  59. Vijver SV, et al. 2021. Front Immunol. 12:733561. PubMed
  60. Cildag S, et al. 2021. Med Pharm Rep. 94:53. PubMed
  61. Bello A, et al. 2021. Immunol Cell Biol. 99:879. PubMed
  62. den Hartigh AB, et al. 2018. Curr Protoc Immunol. :e52. PubMed
  63. Klehmet J, et al. 2014. J Neurol Psychiatry. . PubMed
  64. Chia Y, et al. 2013. Antiviral Res. 3542:354. PubMed
  65. Bulut G, et al. 2013. Blood. 122:3964. PubMed
  66. Clemente V, et al. 2021. Cells. 10: . PubMed
  67. Yen J, et al. 2015. J Leukoc Biol. 98: 689-702. PubMed
  68. Ozawa T, et al. 2021. iScience. 24:102488. PubMed
  69. Sinha D, et al. 2020. Anal Biochem. 113827:608. PubMed
  70. Tsanov K, et al. 2016. Nat Cell Biol. 19:60-67. PubMed
  71. Baerenwaldt A, et al. 2016. J Immunol. 196: 2561 - 2571. PubMed
  72. Dinter J, et al. 2015. J Mol Endocrinol. 54:205. PubMed
  73. Makowski EK, et al. 2021. MAbs. 13:1951426. PubMed
  74. Kiriakidis S, et al. 2017. Kidney International. 10.1016/j.kint.2017.03.008. PubMed
  75. Basnayake K, et al. 2010. J Am Soc Nephrol. 1.684027778. PubMed
  76. Sun X, et al. 2013. J Immunol. 190:2536. PubMed
  77. Balmer M, et al. 2014. Sci Transl Med. 21:237. PubMed
  78. Wu C, et al. 2014. Cancer Epidemiol Biomarkers Prev. 23:1569. PubMed
  79. Kim DJ, et al. 2020. Proc Natl Acad Sci U S A. 117:15837. PubMed
  80. Parrish H, et al. 2016. Proc Natl Acad Sci U S A. 113: 3000 - 3005. PubMed
  81. Ugurlu-Çimen D, et al. 2021. Epigenetics Chromatin. 14:32. PubMed
  82. Phan T, et al. 2013. Biochem Pharmacol. 85:1145. PubMed
  83. Sadovskaya I, et al. 2014. Carbohydr Polym. 111:139. PubMed
  84. Xing QR, et al. 2020. Sci Adv. 6:00. PubMed
  85. Gröschel C, et al. 2018. Front Immunol. 9:2665. PubMed
  86. Buschor S, et al. 2017. PLoS Pathogens. 13(6):e1006476. PubMed
  87. von Wenserski L, et al. 2020. Leukemia. . PubMed
  88. Isernhagen A, et al. 2015. EMBO Mol Med. 7: 1480 - 1502. PubMed
  89. Shinohara M 2015. J Immunol. 194:5635. PubMed
  90. Liu T, et al. 2015. Infect Immun . 83:2011. PubMed

Related FAQs

There are no FAQs for this product.
Go To Top Version: 6    Revision Date: 12/12/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account